171 related articles for article (PubMed ID: 8556529)
21. Monoclonal antibody mediated capsular reactions (Quellung) in Cryptococcus neoformans.
Mukherjee J; Cleare W; Casadevall A
J Immunol Methods; 1995 Jul; 184(1):139-43. PubMed ID: 7622865
[TBL] [Abstract][Full Text] [Related]
22. Molecular and idiotypic analysis of antibodies to Cryptococcus neoformans glucuronoxylomannan.
Casadevall A; DeShaw M; Fan M; Dromer F; Kozel TR; Pirofski LA
Infect Immun; 1994 Sep; 62(9):3864-72. PubMed ID: 8063403
[TBL] [Abstract][Full Text] [Related]
23. [Recognition of intact cells from Cryptococcus neoformans by the anti-glucuronoxylomannan 4B3 monoclonal antibody].
Gato Armas R; Martínez Machín G; Rodríguez Sánchez H; Otero González A; Sarracent Pérez J; Illnait Zaragozi MT
Rev Cubana Med Trop; 2006; 58(2):159-61. PubMed ID: 23427436
[TBL] [Abstract][Full Text] [Related]
24. Human microglia mediate anti-Cryptococcus neoformans activity in the presence of specific antibody.
Lee SC; Kress Y; Dickson DW; Casadevall A
J Neuroimmunol; 1995 Oct; 62(1):43-52. PubMed ID: 7499491
[TBL] [Abstract][Full Text] [Related]
25. Fc-dependent and Fc-independent opsonization of Cryptococcus neoformans by anticapsular monoclonal antibodies: importance of epitope specificity.
Netski D; Kozel TR
Infect Immun; 2002 Jun; 70(6):2812-9. PubMed ID: 12010967
[TBL] [Abstract][Full Text] [Related]
26. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen.
Martinez LR; Moussai D; Casadevall A
Infect Immun; 2004 Jun; 72(6):3674-9. PubMed ID: 15155683
[TBL] [Abstract][Full Text] [Related]
27. Characterization of a murine monoclonal antibody to Cryptococcus neoformans polysaccharide that is a candidate for human therapeutic studies.
Casadevall A; Cleare W; Feldmesser M; Glatman-Freedman A; Goldman DL; Kozel TR; Lendvai N; Mukherjee J; Pirofski LA; Rivera J; Rosas AL; Scharff MD; Valadon P; Westin K; Zhong Z
Antimicrob Agents Chemother; 1998 Jun; 42(6):1437-46. PubMed ID: 9624491
[TBL] [Abstract][Full Text] [Related]
28. Characterization of Cryptococcus neoformans capsular glucuronoxylomannan polysaccharide with monoclonal antibodies.
Todaro-Luck F; Reiss E; Cherniak R; Kaufman L
Infect Immun; 1989 Dec; 57(12):3882-7. PubMed ID: 2680986
[TBL] [Abstract][Full Text] [Related]
29. Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine.
Pirofski L; Lui R; DeShaw M; Kressel AB; Zhong Z
Infect Immun; 1995 Aug; 63(8):3005-14. PubMed ID: 7622223
[TBL] [Abstract][Full Text] [Related]
30. Monoclonal antibodies to Cryptococcus neoformans glucuronoxylomannan enhance fluconazole efficacy.
Mukherjee J; Feldmesser M; Scharff MD; Casadevall A
Antimicrob Agents Chemother; 1995 Jul; 39(7):1398-405. PubMed ID: 7492075
[TBL] [Abstract][Full Text] [Related]
31. Molecular and idiotypic analyses of the antibody response to Cryptococcus neoformans glucuronoxylomannan-protein conjugate vaccine in autoimmune and nonautoimmune mice.
Nussbaum G; Anandasabapathy S; Mukherjee J; Fan M; Casadevall A; Scharff MD
Infect Immun; 1999 Sep; 67(9):4469-76. PubMed ID: 10456888
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans.
Brandt S; Thorkildson P; Kozel TR
Clin Diagn Lab Immunol; 2003 Sep; 10(5):903-9. PubMed ID: 12965925
[TBL] [Abstract][Full Text] [Related]
33. Hinge influences in murine IgG binding to Cryptococcus neoformans capsule.
Oliveira DSL; Paredes V; Caixeta AV; Henriques NM; Wear MP; Albuquerque P; Felipe MSS; Casadevall A; Nicola AM
Immunology; 2022 Jan; 165(1):110-121. PubMed ID: 34458991
[TBL] [Abstract][Full Text] [Related]
34. The different binding patterns of two immunoglobulin M monoclonal antibodies to Cryptococcus neoformans serotype A and D strains correlate with serotype classification and differences in functional assays.
Cleare W; Casadevall A
Clin Diagn Lab Immunol; 1998 Mar; 5(2):125-9. PubMed ID: 9521132
[TBL] [Abstract][Full Text] [Related]
35. Monoclonal antibodies to Cryptococcus neoformans capsular polysaccharide modify the course of intravenous infection in mice.
Mukherjee S; Lee S; Mukherjee J; Scharff MD; Casadevall A
Infect Immun; 1994 Mar; 62(3):1079-88. PubMed ID: 8112842
[TBL] [Abstract][Full Text] [Related]
36. A glycan FRET assay for detection and characterization of catalytic antibodies to the
Crawford CJ; Wear MP; Smith DFQ; d'Errico C; McConnell SA; Casadevall A; Oscarson S
Proc Natl Acad Sci U S A; 2021 Feb; 118(5):. PubMed ID: 33514659
[TBL] [Abstract][Full Text] [Related]
37. Protective and nonprotective monoclonal antibodies to Cryptococcus neoformans originating from one B cell.
Mukherjee J; Nussbaum G; Scharff MD; Casadevall A
J Exp Med; 1995 Jan; 181(1):405-9. PubMed ID: 7807020
[TBL] [Abstract][Full Text] [Related]
38. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody.
Syme RM; Bruno TF; Kozel TR; Mody CH
Infect Immun; 1999 Sep; 67(9):4620-7. PubMed ID: 10456908
[TBL] [Abstract][Full Text] [Related]
39. Reactivity patterns and epitope specificities of anti-Cryptococcus neoformans monoclonal antibodies by enzyme-linked immunosorbent assay and dot enzyme assay.
Belay T; Cherniak R; Kozel TR; Casadevall A
Infect Immun; 1997 Feb; 65(2):718-28. PubMed ID: 9009335
[TBL] [Abstract][Full Text] [Related]
40. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
